USPTO serial 99431659
PROTEIMER
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- ZAVALA DIEK, JOSEPH MARCO
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Deadline: January 7th, 2027
Need help with PROTEIMER?
CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.
Owner
HyunDae Cho
Carlsbad, CA, US
HyunDae Cho
Carlsbad, CA, US
CrossLife Technologies Inc.
Carlsbad, CA, US
CrossLife Technologies Inc.
Carlsbad, CA, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; therapeutic proteins, namely, targeted binding proteins engineered for high-affinity and specificity to disease-associated targets, for use in modulating cellular signaling pathways and disease progression; biologic preparations for the treatment of oncological, neurological, metabolic, and immunological disorders; aptamer-based therapeutic agents for targeted treatment of cancer, including immune cell engagers that recruit and activate immune effector cells, including T cells and natural killer (NK) cells, against tumor cells, and for targeted delivery of therapeutic payloads, including cytotoxic agents, nucleic acids, and protein therapeutics, to specific human tissues; protein-based drug candidates, namely, multi-specific and modular biopharmaceutical preparations for the treatment of cancer and neurological and neurodegenerative diseases; antibody mimetics being engineered proteins for targeted modulation of disease pathways, selective receptor agonism or antagonism, blood-brain barrier penetration, and delivery of therapeutic agents to human tissue | ACTIVE | — |
| 042 | Scientific and technological research and design in the fields of biotechnology, pharmaceutical development, research and development of protein-based therapeutics, aptamer-based drug discovery platforms, biologic drug delivery systems, and biologically active molecules for therapeutic use; providing information in the field of scientific research and design in biotechnology | ACTIVE | — |
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 7, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 12, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 17, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 13, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 13, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 11, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 7, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 7, 2025 | NWAP | NEW APPLICATION ENTERED | — |